Annovis Bio, Inc.

NYSE:ANVS Stock Report

Market Cap: US$69.1m

Annovis Bio Management

Management criteria checks 2/4

Annovis Bio's CEO is Maria Maccecchini, appointed in May 2008, has a tenure of 16.58 years. total yearly compensation is $2.15M, comprised of 31.1% salary and 68.9% bonuses, including company stock and options. directly owns 7.96% of the company’s shares, worth $5.50M. The average tenure of the management team and the board of directors is 0.9 years and 8.9 years respectively.

Key information

Maria Maccecchini

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage31.1%
CEO tenure16.6yrs
CEO ownership8.0%
Management average tenureless than a year
Board average tenure8.9yrs

Recent management updates

Recent updates

We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

Dec 06
We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

Annovis Bio To Continue Alzheimer's Disease Clinical Trials

Oct 17

Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom

Sep 27

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints

Jul 08

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease

Jun 30

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

May 02

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Feb 12

Annovis And Alzheimer's Disease: The Best-Laid Plans

Jan 30

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials

Jan 20

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts

Oct 16

Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Sep 08
Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Jun 28

Annovis wins EU nod to expand late-stage trial for Parkinson's candidate

Feb 08

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Jan 28
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug

Jan 25

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Oct 06

We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Sep 15
We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Annovis Bio announces publication of three U.S. patents covering lead asset

Sep 13

Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate

Aug 24

Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate

Jul 07

Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

May 14
Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Feb 10
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Apr 16
Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

Feb 23
Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

Jan 01
We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Maria Maccecchini's remuneration changed compared to Annovis Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$43m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$2mUS$668k

-US$56m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$3mUS$636k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$9mUS$510k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$1mUS$420k

-US$5m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$120kUS$120k

-US$991k

Sep 30 2019n/an/a

-US$958k

Jun 30 2019n/an/a

-US$841k

Mar 31 2019n/an/a

-US$715k

Dec 31 2018US$155kUS$120k

-US$714k

Compensation vs Market: Maria's total compensation ($USD2.15M) is above average for companies of similar size in the US market ($USD651.40K).

Compensation vs Earnings: Maria's compensation has been consistent with company performance over the past year.

CEO

Maria Maccecchini (73 yo)

16.6yrs

Tenure

US$2,145,852

Compensation

Dr. Maria L. Maccecchini, Ph D., serves as Independent Director of Lantern Pharma Inc. from June 08, 2022. She is the Founder of Annovis Bio, Inc. and has been its Chief Executive Officer and President sin...

Leadership Team

NamePositionTenureCompensationOwnership
Maria Maccecchini
Founder16.6yrsUS$2.15m7.96%
$ 5.5m
Mark White
Chief Business Officer & Directorless than a yearUS$135.43k0.44%
$ 306.4k
William Fricker
Chief Financial Officerno datano datano data
Cheng Fang
Senior Vice President of Research & Development2.9yrsno datano data
Eve Damiano
Senior Vice President of Regulatory Operations2.9yrsno datano data
Melissa Gaines
Senior Vice President of Clinical Operations1.3yrsno datano data
Blake Jensen
Head of Qualityless than a yearno datano data
Hilda Maibach
Senior Vice President of Statisticsless than a yearno datano data

0.9yrs

Average Tenure

68yo

Average Age

Experienced Management: ANVS's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Maria Maccecchini
Founder16.6yrsUS$2.15m7.96%
$ 5.5m
Mark White
Chief Business Officer & Director8.9yrsUS$135.43k0.44%
$ 306.4k
Michael M. Hoffman
Independent Chairman of the Board10.9yrsUS$153.92k11.88%
$ 8.2m
Jeffrey Cummings
Chief Medical Advisor & Member of Scientific Advisory Boardno datano datano data
Gregory Petsko
Member of Scientific Advisory Board7.9yrsno datano data
Reid McCarthy
Independent Director3.7yrsUS$143.92k0.053%
$ 36.6k
Sidney Strickland
Chairman of Scientific Advisory Board7.9yrsno datano data
Claudine Bruck
Independent Director9.9yrsUS$135.43k0.048%
$ 32.9k

8.9yrs

Average Tenure

71.5yo

Average Age

Experienced Board: ANVS's board of directors are considered experienced (8.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:43
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Annovis Bio, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tyler BussianBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity
Jason KolbertD. Boral Capital LLC.